Search

Displaying results 2051 - 2060 of 10000 in total
  1. Drug

    Amber

    go.drugbank.com/drugs/DB14326
    Investigational

    Amber is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: Ma Ying Long HemorrhoidalCategories: Compounds used in a research, industrial, or household setting
  2. Drug

    Apadamtase alfa

    go.drugbank.com/drugs/DB15164
    ApprovedInvestigational

    [A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP. … [A262076] Patients with cTTP have a severe deficiency of a plasma metalloproteinase called ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), which is responsible

  3. Drug

    Polatuzumab vedotin

    go.drugbank.com/drugs/DB12240
    ApprovedInvestigational

    Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. … [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141]

  4. Drug

    Flavoxate

    go.drugbank.com/drugs/DB01148
    Approved

    A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. … It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem]

  5. Drug

    Sodium oxybate

    go.drugbank.com/drugs/DB09072
    ApprovedInvestigational

    [A18723] For safety reasons, sodium oxybate is a controlled substance only available through a restricted program in approved countries. … [L30598] It is a sodium salt of [gamma-Hydroxybutyric acid], an endogenous cerebral inhibitory neurotransmitter [A251445] and a metabolite of the inhibitory neurotransmitter GABA.

  6. Drug

    Ceritinib

    go.drugbank.com/drugs/DB09063
    ApprovedInvestigational

    Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key "gatekeeper" residues of the enzyme. … The FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide
  7. Drug

    Pidolic acid

    go.drugbank.com/drugs/DB03088
    ApprovedInvestigational

    Pidolic acid is a naturally occurring but little-studied amino acid derivative that can be formed enzymatically or non-enzymatically and participates as a biological intermediate with unique pharmacodynamics … Pidolic acid, in general, is found in large quantities in brain tissue and other tissues in bound form, like skin [L2729].

    Synonyms: 5-L-oxoproline, 5-oxo-L-proline
  8. Drug

    CX-052075

    go.drugbank.com/drugs/DB31655
    Approved

    [L53408] It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna. … CX-052075 is a nucleoside-modified messenger RNA (mRNA) encoding the N-terminal domain (NTD) and receptor-binding domain (RBD) of the spike glycoprotein of the SARS-CoV-2 Omicron variant sublineage LP.8.1

  9. Drug

    Brepocitinib

    go.drugbank.com/drugs/DB15003
    ApprovedInvestigational

    Brepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults. … [L64097] The FDA approved brepocitinib on August 27, 2026 for the treatment of dermatomyositis in adult patients, making it the first targeted oral therapy approved for the condition.[L64115]

  10. Drug

    Palovarotene

    go.drugbank.com/drugs/DB05467
    Approved

    [L39990,L40020] It has been granted rare pediatric disease and breakthrough therapy designations from the US FDA, although a previously submitted NDA was withdrawn in August 2021 pending the resubmission … [A244920] FOP is caused by a gain-of-function mutation in the ACVR1/ALK2 gene which results in progressive heterotopic ossification, a process wherein connective tissues (e.g. skeletal muscle, ligaments